Healthcare / BiotechnologyNasdaqCM
$0.09
-0.03 (-23.54%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-19.2M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$70495
P/E
N/A
•EV/EBITDA
N/A
•ROE
-743.6%
↓Gross Margin
8.4%
↓Debt/Equity
0.54
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-804447.6%
FCF / Net income
0.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3195.0 · net income $-41.7M · FCF $-25.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $3195.00 | $3195.00 | $133985.00 | $645176.00 | $933715.00 | $105034.00 | — | — |
| Net Income | $-41.7M | $-41.7M | $-34.4M | $-32.4M | $-27.6M | $-46.4M | $-9.1M | $-5.8M |
| EBITDA | $-40.1M | $-40.1M | $-27.0M | $-25.5M | $-24.8M | — | — | — |
| EPS | -2828.18 | -2828.18 | -8070699.40 | -249623.74 | -2768755.30 | -1183104576000.00 | — | — |
| Gross Margin | 8.4% | 8.4% | -368.3% | -17.3% | 17.9% | 25.8% | — | — |
| Operating Margin | -612542.2% | -612542.2% | -20796.1% | -4039.6% | -2670.6% | -39925.1% | — | — |
| Net Margin | -1305608.8% | -1305608.8% | -25709.2% | -5018.9% | -2961.3% | -44148.9% | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.54 | 0.54 | 4.13 | 1.13 | 0.65 | — | — | — |
| Current Ratio | 0.06 | 0.06 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-25.7M | $-25.7M | $-16.8M | $-19.2M | $-22.8M | — | — | — |
| Returns | ||||||||
| ROE | -743.6% | -743.6% | -2057.0% | -201.7% | -531.1% | -455.5% | -83.1% | 204.3% |
| Valuation | ||||||||
| P/B | 0.00 | 0.00 | 3.79 | 10136.17 | 24528.45 | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -97.6% | -97.6% | -79.2% | -30.9% | — | — | — | — |
| EPS Growth | 100.0% | 100.0% | -3133.1% | 91.0% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-100.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-8070699.40 → -2828.18
Residual
-100.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.